Research programme: cancer therapeutics - Isomerase Therapeutics

Drug Profile

Research programme: cancer therapeutics - Isomerase Therapeutics

Latest Information Update: 08 Aug 2011

Price : $50

At a glance

  • Originator Biotica Technology
  • Developer Isomerase Therapeutics
  • Class Macrolides
  • Mechanism of Action G protein-coupled receptor GPR78 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 08 Aug 2011 Cancer therapeutics programme available for partnering/licensing following preclinical proof-of-concept studies. http://www.biotica.com
  • 27 Jan 2011 Early research is ongoing in the United Kingdom
  • 06 Jun 2007 Early research in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top